Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Refractory Painful Care in a Palliative Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of ≥18 years old, hospitalized in palliative care units~* Conscious or presenting altered/disturbed consciousness but for whom the Rudkin score is ≤ 4 (eyes closed, response to light tactical stimulation)~* For whom a palliative care is acted~* No matter the progression and prognostic status~* After the information is given to the patient (with the notification form given) and the written consent form is retrieved and when the state of cognition and vigilance allows it. In case of cognitive and consciousness disturbance, after informing and retrieving the written consent form from the patient's trusted person, or a relative by default, for patients under guardianship after being informed and giving a consent form written by the legal representative.~* Evened out on an analgesia level, without care~* Who has not received ketamine for 60 days before inclusion no matter the indications~* For whom bedsore, ulcer or vascular injuries have appeared and continue to be painful despite the administration of opioid bolus with the painful evaluation regarding the visual analogic scale (EVA) ≥ 5/10, or regarding the evaluation of the Algoplus pain behavior scale ≥ 2, or for whom the opioid treatment cannot be administered due to the presence of adverse side effects (drowsiness, confusion, nausea, vomiting, respiratory depression...)~* And for whom caring under Entonox (a medical analgesic gas which is a mix of nitrous oxide and oxygen) is inefficient or not compatible.~* Lack of easy venous access~Exclusion Criteria:~* Contraindication of Ketamine in case of anesthesia (AMM) : allergy, porphyria~* Late stage heart failure~* Intracranial hypertension~* Acute heart attack phase~* Unstable psychosis~* Presence of agitation~* Pregnant woman~* Patient with no affiliation to a social security system~* Contraindication of Midazolam: known hypersensitivity to benzodiazepines or any other know excipient of the product, acute respiratory depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- communicating and none-communicating patients (Type: EXPERIMENTAL): 20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)

Based on this trial design, predict the completion outcome and termination type (if applicable).